期刊
EXPERIMENTAL HEMATOLOGY
卷 41, 期 4, 页码 387-397出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.exphem.2012.11.005
关键词
-
资金
- Celgene SRL Italy
- International Myeloma Foundation
- Italian Minister of Health-Progetti Regione Emilia Romagna
- Associazione Italiana per la Ricerca sul Cancro [IG2099, 8530, 9965, IG4569]
Multiple myeloma (MM) induced osteoclast (OC) formation is mainly due to an imbalance of the receptor activator NF-kappa B ligand (RANKL)-osteoprotegerin (OPG) ratio in favor of RANKL in the bone microenvironment and to the CCL3 production by MM cells. The purpose of the study was to investigate the effect of the immunomodulatory drugs on RANKL/OPG ratio, the production of pro-osteoclastogenic cytokines, and MM-induced OC formation. We found that in vivo concentrations of both lenalidomide (LEN) and pomalidomide (POM) significantly blunted RANKL upregulation normalizing the RANKL/OPG ratio in human osteoprogenitor cells (PreOBs) when co-cultured with MM cells and also inhibited CCL3 production by MM cells. A reduction in CD49d expression, a molecule critically involved in RANKL upregulation in the MM microenvironment, accompanied this effect. Consistently, the pro-osteoclastogenic property of MM cells co-cultured with PreOBs was reduced by both LEN and POM. We further investigated the effect of these drugs on the transcriptional profile of both MM cells and PreOBs by microarray analysis, which showed that adhesion molecules, such as ITGA8 and ICAM2, are significantly downregulated in MM cells. Our data suggest that LEN and POM inhibit MM-induced OC formation through normalization of the RANKL/OPG ratio targeting the expression of adhesion molecules by MM cells. (C) 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据